{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:03:00Z","timestamp":1780362180813,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T00:00:00Z","timestamp":1444348800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12903-015-0102-y","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T15:00:45Z","timestamp":1444402845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A case report: retigabine induced oral mucosal dyspigmentation of the hard palate"],"prefix":"10.1186","volume":"15","author":[{"given":"Nicholas G.","family":"Beacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,9]]},"reference":[{"key":"102_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug-resistant epilepsy: conscensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51:1069\u201377.","journal-title":"Epilepsia"},{"key":"102_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/epi.12605","volume":"55","author":"G Bell","year":"2014","unstructured":"Bell G, Neligan A, Sander J. An unknown quantity \u2013 the worldwide prevalence of epilepsy. Epilepsia. 2014;55:958\u201362.","journal-title":"Epilepsia"},{"key":"102_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/seiz.2000.0422","volume":"9","author":"J Wright","year":"2000","unstructured":"Wright J, Pickard N, Whitfield A, Hakin N. A population-based study of the prevalence, clinical characteristics and effect of ethnicity in epilepsy. Seizure. 2000;9:309\u201313.","journal-title":"Seizure"},{"key":"102_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","volume":"78","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Barry SJE, Bamagous GA, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548\u201354.","journal-title":"Neurology"},{"issue":"4","key":"102_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nrl.2012.04.012","volume":"28","author":"V Villanueva","year":"2013","unstructured":"Villanueva V, Gir\u00f3n JM, Mart\u00edn J, Hern\u00e1ndez-Pastor LJ, Lahuerta J, Doz M, et al. Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study. Neurologia. 2013;28(4):195\u2013204.","journal-title":"Neurologia"},{"issue":"20","key":"102_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","volume":"75","author":"MJ Brodie","year":"2010","unstructured":"Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817\u201324. doi: 10.1212\/WNL.0b013e3181fd6170 . Epub 2010 Oct 13.","journal-title":"Neurology"},{"issue":"18","key":"102_CR7","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","volume":"76","author":"JA French","year":"2011","unstructured":"French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555\u201363.","journal-title":"Neurology"},{"key":"102_CR8","unstructured":"European Medicines Agency. 2011. CHMP Assessment Report; retigabine. Procedure No.EMEA\/H\/C\/001245. EMA London. 20 January 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/001245\/WC500104839.pdf"},{"issue":"8","key":"102_CR9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.clinthera.2013.06.012","volume":"35","author":"DJ Tompson","year":"2013","unstructured":"Tompson DJ, Crean CS, Reeve R, Berry NS. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures. Clin Ther. 2013;35(8):1174\u201385.","journal-title":"Clin Ther"},{"key":"102_CR10","unstructured":"F.D.A.2013. FDA Drug Safety Communication: FDA approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration. FDA, Maryland. 26 April 2013. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm372774.htm"},{"issue":"9","key":"102_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamadermatol.2013.8895","volume":"150","author":"TG Shkolnik","year":"2014","unstructured":"Shkolnik TG, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150(9):984\u20139.","journal-title":"JAMA Dermatol"},{"key":"102_CR12","unstructured":"Huber B, Bocchicchio M. A retrospective evaluation of retigabine in patients with high therapy-resistant epilepsy. Epilepsy and Behavior, in press."},{"issue":"4","key":"102_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cden.2013.07.006","volume":"57","author":"F Alawi","year":"2013","unstructured":"Alawi F. Lesions of the oral cavity: an update. Dent Clin North America. 2013;57(4):699\u2013710.","journal-title":"Dent Clin North America"},{"issue":"3","key":"102_CR14","doi-asserted-by":"publisher","first-page":"10.1016","DOI":"10.1016\/j.oooo.2013.05.023","volume":"116","author":"SO Akintoye","year":"2013","unstructured":"Akintoye SO, Boyce AM, Collins MT. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(3):10.1016.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"102_CR15","doi-asserted-by":"publisher","first-page":"M33","DOI":"10.1530\/EJE-15-0464","volume":"173","author":"L Nieman","year":"2015","unstructured":"Nieman L. Cushing\u2019s: Update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015;173(4):M33\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"4\u20135","key":"102_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.autrev.2014.01.025","volume":"13","author":"RA Brand\u00e3o Neto","year":"2014","unstructured":"Brand\u00e3o Neto RA, de Carvalho JF. Diagnosis and classification of Addison\u2019s disease (autoimmune adrenalitis). Autoimmun Rev. 2014;13(4\u20135):408\u201311.","journal-title":"Autoimmun Rev"},{"key":"102_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1746-160X-10-8","volume":"10","author":"L Feller","year":"2014","unstructured":"Feller L, Masilana A, Khammissa RAG M, Jadwat Y, Lemmer J. Melanin: the biophysiology of oral melanocytes and physiological oral pigmentation. Head Face Med. 2014;10:8.","journal-title":"Head Face Med"},{"issue":"3","key":"102_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1529-8019.2010.01319.x","volume":"23","author":"S M\u00fcller","year":"2010","unstructured":"M\u00fcller S. Melanin-associated pigmented lesions of the oral mucosa: presentation, differential diagnosis, and treatment. Dermatol Ther. 2010;23(3):220\u20139.","journal-title":"Dermatol Ther"},{"issue":"1","key":"102_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1875-595X.2008.tb00170.x","volume":"58","author":"MJ McCullough","year":"2008","unstructured":"McCullough MJ, Tyas MJ. Local adverse effects of amalgam restorations. Int Dent J. 2008;58(1):3\u20139.","journal-title":"Int Dent J"},{"key":"102_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0738-081X(00)00148-6","volume":"18","author":"D Eisen","year":"2000","unstructured":"Eisen D. Disorders of pigmentation in the oral cavity. Clin Dermatol. 2000;18:579\u201387.","journal-title":"Clin Dermatol"},{"issue":"1","key":"102_CR21","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.4317\/medoral.16.e11","volume":"16","author":"G Mergoni","year":"2011","unstructured":"Mergoni G, Ergun S, Vescovi P, Mete O, Tanyeri H, Meleti M. Oralpostinflammatory pigmentation: an analysis of 7 cases. Med Oral Patol Oral Cir Bucal. 2011;16(1):e11\u20134.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"6","key":"102_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.tripleo.2003.11.006","volume":"97","author":"NS Treister","year":"2004","unstructured":"Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(6):718\u201325.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11584860-000000000-00000","volume":"25","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy. Newly approved and developmental agents. CNS Drugs. 2011;25:89\u2013107.","journal-title":"CNS Drugs"},{"issue":"3","key":"102_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","volume":"53","author":"MJ Gunthorpe","year":"2012","unstructured":"Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53(3):412\u201324.","journal-title":"Epilepsia"},{"key":"102_CR25","unstructured":"European Medicines Agency. 2013. European Medicines Agency recommends restricting Trobalt to last-line therapy in partial epilepsy Procedure No.EMEA\/H\/C\/001245. EMA, London. 20 January 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/human\/001245\/WC500143799.pdf"},{"key":"102_CR26","unstructured":"Prescott J, Evans C, Saenz AA. 2014. Pigmentary abnormalities (discolouration) associated with exogabine\/retigabine treatment: non clinical aspects. Presented at American Epilepsy Society, Seattle, Washington, USA, 5-9th December."}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-015-0102-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12903-015-0102-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-015-0102-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T19:59:54Z","timestamp":1475351994000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-015-0102-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1186\/s12903-015-0102-y","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,9]]},"article-number":"122"}}